Under collaboration, TSRI to test Yisheng's adjuvant in HIV vaccines

The Scripps Research Institute will team up with China's Yisheng Biopharma to test the biotech's adjuvant in HIV vaccines. Pictured is a Scripps lab in Florida.

Seeking to address a top public health priority, The Scripps Research Institute (TSRI) has teamed with China’s Yisheng Biopharma with hopes of advancing vaccine research against HIV.

Through the deal, Scripps will test its vaccine technology in conjunction with Yisheng’s PIKA adjuvant. The biotech says its adjuvant has undergone Phase II testing in rabies and Phase I testing in hepatitis B with positive results thus far.

PIKA is a Toll-like receptor 3 agonist that TSRI believes “could activate innate immune signaling and induce a more robust immune response that confers protection against HIV infection” when paired with HIV vaccines, TSRI assistant professor Jiang Zhu said in a statement.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

In preclinical work to date, Yisheng’s adjuvant has “exhibited broad potential” in disease areas such as rabies, HIV, hep B, influenza and tuberculosis, the company said in its statement.

For TSRI, the collaboration follows a series of scientific advances against HIV, most recently in September when a team there identified antibodies that could potentially target “holes” in the deadly virus’ defensive shield. Earlier in the same month, a group led by TSRI and the International AIDS Vaccine Initiative published findings showing that the immune system can be manipulated to advance the development of antibodies against the virus.

While that work is early, the NIH recently unveiled plans to start a large, late-stage trial of vaccine candidate HVTN 100 in South Africa later this year. That vaccine--made up of one experimental vaccine each supplied by Sanofi Pasteur and GlaxoSmithKline--will undergo testing in 5,400 HIV-uninfected men and women.

Other institutions involved in the global effort to develop an HIV vaccine are the University of Maryland, Texas Biomed, UMass, Duke University and Johnson & Johnson. Across the pond, the European Commission established a €23 million ($25 million) collaboration last year that involves 22 companies and organizations aimed at creating an HIV vaccine.

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.